The efficacy of arsenic trioxide (As 2 O 3 ) in the treatment of newly diagnosed and relapsed acute promyelocytic leukemia (APL) has been well established.
1 Unlike all-trans retinoic acid (ATRA), which though effective as a single agent fails to induce molecular remission, single agent As 2 O 3 can induce molecular remission consistently in the majority of patients. 1 Arsenic trioxide is well tolerated and is not associated with conventional toxicities of chemotherapy such as grade 3/4 mucositis and neutropenia. These advantages have resulted in single agent As 2 O 3 replacing ATRA, chemotherapy or a combination of ATRA and chemotherapy in the treatment of patients with relapsed APL. 1 Concerns have been raised about the potential for fatal cardiac and hepatic toxicity 1 in a subset of patients with APL who were treated with As 2 O 3 . However, most of these toxicities have been described in patients with relapsed APL who had received multiple courses of chemotherapy and had significant comorbidity. There are limited data on the toxicity profile of As 2 O 3 and its impact on clinical outcomes when used in the treatment of patients with newly diagnosed APL who do not have significant comorbid conditions.
It has been noted that there is considerable interindividual variation in susceptibility to As 2 O 3 -induced toxicity, which is probably related to differences in in vivo biotransformation of arsenic. In addition to a poorly characterized arsenic methyltransferase, a number of other enzyme systems and genetic polymorphisms have been shown to have an effect on arsenic methylation. 2 Of these, polymorphisms in the methylene tetrahydrofolate reductase (MTHFR) gene and those of the glutathione S-transferases (GST) family of proteins have been noted to have an impact on the metabolism and toxicity profile of inorganic arsenic. 3, 4 We report the hepatotoxicity profile in a cohort of patients with newly diagnosed APL treated at our center, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity.
Archival genomic DNA samples of patients were analyzed after obtaining written informed consent. Previously published polymerase chain reaction (PCR) and restriction digestion protocols were used to genotype the GSTA1, 5 MTHFR C677T and MTHFR A1298C 6 polymorphisms. The genotype assignments were made by electrophoretic analysis of the amplified product in 3% agarose gel. An established multiplex PCR reaction was used for identification of GST M1 and GST T1 polymorphisms. 7 The multiplex PCR procedure used for GST M1 and GST T1 genotype analysis clearly identifies the homozygous null genotype but does not discriminate the deletional heterozygotes and non-deletional homozygotes, which were classified as GST MI or GST T1 positive genotypes. An internal albumin control was used in the multiplex PCR procedure for the detection of GST M1 and GST T1 null genotypes. The genotype assignments of GST M1 and GST T1 were made by electrophoretic analysis of the amplified product in 2% agarose gel.
Between January 1998 and April 2005, 83 patients with newly diagnosed PML/RARa þ APL were treated with a regimen of single agent As 2 O 3 . The details of the regimen, the supportive care that was administered, the indications for administration of hydroxyurea or an anthracycline in induction and the clinical outcome with this regimen have been reported earlier. 8 Briefly, the regimen consisted of As 2 O 3 administered daily at a dose of 10 mg/day for adults and 0.15 mg/kg for the pediatric population till hematological remission (CR) or for a maximum of 60 days. Following a 4-week interval, it was administered at the same dose for an additional 4 weeks as a consolidation course in those patients who were in CR. Following a second 4-week interval after consolidation, it was administered as a maintenance course at the same doses for 10 days a month for 6 months.
There were seven early deaths (mean 4.3 days, range: 2-7) secondary to intracranial (IC) bleeds, but none of these patients had baseline liver function abnormalities or developed hepatic dysfunction before their death. These seven patients were excluded from further analysis in this study, as they could not be evaluated for the hepatotoxic effect of As 2 O 3 . The baseline characteristics of the remaining 76 patients and the influence of these parameters on the incidence of hepatotoxicity are summarized in Table 1 .
Of the 76 patients who could be evaluated for hepatotoxicity in this study, 73 (96%) achieved complete hematological remission (CR). The remaining three patients died on days 20, 23 and 49 from uncontrolled sepsis, IC bleed and a differentiation syndrome, respectively. Eight patients (10.5%) received an anthracycline in induction. Mitoxantrone was administered at a dose of 10 mg/m 2 to seven patients, five of them received one dose whereas two received two doses on consecutive days. Daunorubicin was administered to one patient at a dose of 45 mg/m 2 on 2 consecutive days. Indications for administration of an anthracycline in induction included a differentiation syndrome in two patients, and in six cases a high leukocyte count at presentation or a rapid leukocytic response (as defined previously). 8 Hydroxyurea was administered to 58 (76.3%) patients for high leukocyte count at presentation or a leukocytic response following administration of As 2 O 3 . Hydroxyurea was administered in induction for a median period of 12 days (range: 2-32) and a median cumulative dose of 13 g (range: 1-40.5). The event-free survival (EFS), overall survival (OS) and diseasefree survival (DFS) with this regimen have been previously reported by us. 8 Among the 76 patients who could be evaluated in this study for hepatotoxicity, at a median follow-up of 24 months (range: 4-92), the 3-year Kaplan-Meier estimate of OS, EFS and DFS was 96.0572.23, 85.8674.81 and 87.0775%, respectively.
Of the 76 patients evaluated, there was no evidence of hepatotoxicity in 47 (61.8%). Grade 1, 2, 3 and 4 toxicity (NCI-CTC v2.0) was seen in 14 (18.4%), 7 (9.2%), 4 (5.3%) and 4 (5.3%) patients, respectively. The onset of hepatotoxicity occurred in induction in 19 (65.5%), during consolidation in three (10.3%), during maintenance in six (20.7%) and following completion of therapy in one patient (3.4%). Of the 29 (38.2%) patients who developed hepatotoxicity, elevated liver enzymes were seen in 28 (96.6%) and was the prominent abnormality in these patients. It was transient (o4 weeks duration) in 20 (68.9%). It resolved on continuing As 2 O 3 in 21 (72.4%). For the eight patients with grade 3/4 toxicity, As 2 O 3 was withheld till the liver function tests had returned to a level below grade 3. Arsenic trioxide was withheld in these patients for an average of 22.6 days (range: 10-28). Seven of these patients were successfully re-challenged with As 2 O 3 and completed the rest of their schedule uneventfully. None of these seven patients had recurrence of grade 3/4 hepatotoxicity on continuing therapy with As 2 O 3 nor was there evidence of hepatic compromise/ decompensation on follow-up. One patient had recurrent hepatotoxicity on re-challenging with As 2 O 3, and the drug was discontinued. Two patients with grade 4 hepatotoxicity had documented acute hepatitis B infection. One patient with grade 2 toxicity died on day 42, secondary to uncontrolled sepsis, which probably contributed to hepatic dysfunction. These patients were included in the analysis under the group that developed hepatotoxicity secondary to As 2 O 3, as it would not be possible to exclude As 2 O 3 having contributed to the liver dysfunction. Hepatic dysfunction persisted in two patients after completion of therapy (one each grade 1 and grade 2). There were no cases of acute hepatic failure or mortality attributable to hepatic toxicity. It remains unclear at this point as to why hepatic toxicity did not recur on re-challenging seven of the patients who developed grade 3/4 hepatotoxicity. It has been noted in the differentiation syndrome with ATRA that rechallenging with ATRA after the syndrome has resolved does not lead to recurrence of the syndrome in all patients who initially developed it. 9 Potentially a similar effect is seen with hepatotoxicity and As 2 O 3 , with the side effect being a function of both the drug and the disease, and in the period of drug withdrawal there is an interval improvement in the disease, which limits the side effect when re-challenged.
As illustrated in Table 1 , none of the routine baseline clinical or laboratory parameters were predictive of the subsequent development of hepatotoxicity. Of the 76 patients, genetic polymorphism data were available in 74. In the remaining two cases, archival DNA samples were not available; of these two patients, one did not develop hepatotoxicity whereas the other developed grade 3 hepatotoxicity. The incidence of genetic polymorphisms analyzed in this series was not different from that of the general population studied previously at our center (data not shown).
The presence of the homozygous mutant polymorphism of MTHFR 1298 (C/C) was significantly associated with the development of hepatotoxicity (RR ¼ 8.75, P ¼ 0.004). None of the other polymorphisms that were analyzed was significantly associated with an increased risk of developing hepatotoxicity (Table 1) . However, GST M1 null genotype was associated with a 3.28-fold increased risk of hepatotoxicity, with a trend toward significance (P ¼ 0.06).
There was no significant difference in achieving or time to achieving CR in the group that developed hepatotoxicity and the group that did not (median time to CR: 43 versus 42 days, respectively). The 3-year Kaplan-Meier estimate of OS, EFS and DFS in the group that did not develop hepatotoxicity and the group that did was 95.7472.94, 81.1476.57, 81.3176.95 and 96.5573.39, 96.5573.39, 10070, respectively. Statistical analysis by log-rank test of the survival curves between these two groups did not show a statistically significant difference for OS, EFS or DFS. There was also no statistically significant evidence of a difference in EFS or DFS among patients based on the genetic polymorphisms that were analyzed.
In this series, of the 73 patients who achieved CR, six patients subsequently relapsed. It was of interest to note that none of these relapsed cases had any evidence of hepatotoxicity. Although this observation did not attain statistical significance, there was a trend to a better DFS in the group that developed hepatotoxicity (P ¼ 0.085).
Other adverse events seen with this regimen have been reported earlier. 8 The majority of such adverse events were mild and did not warrant discontinuing therapy. There were no sudden deaths attributable to a cardiac event in this series of patients, and on follow-up there were no documented second malignancies.
This study shows that when single agent As 2 O 3 is used for induction, consolidation and maintenance in the treatment of newly diagnosed cases of APL, it is associated with minimal hepatic toxicity and is well tolerated. It is also associated with durable remissions, which are comparable to conventional ATRA plus chemotherapy regimens. 8 There are no published data commenting on the impact of hepatotoxicity on long-term outcome. In our series, the incidence of hepatotoxicity had no impact on achieving CR nor did it adversely affect OS, EFS or DFS.
The statistically significant increased risk for patients with the homozygous mutation of MTHFR 1298 (C/C) to develop hepatotoxicity suggests that it alters the biotransformation of As 2 O 3 . We hypothesize that polymorphisms of the MTHFR gene have an effect on As 2 O 3 methylation, which is an important pathway of biotransformation of this substance. This alteration in biotransformation possibly leads to quantitative and qualitative differences in the methylated intermediaries that are generated, which in turn could have a bearing on the toxicity profile of As 2 O 3 . A trend toward an increased risk for hepatotoxicity was also noted in this series with the GST M1 null phenotype. It has been noted that this polymorphism is also associated with alterations in the methylation of inorganic arsenic. 4 A better understanding of the pathways of biotransformation of As 2 O 3 and the impact of genetic polymorphisms on its biotransformation could be useful in predicting efficacy and toxicity. Although in this series of newly diagnosed patients the toxicity profile was mild and their prediction would not have contributed significantly to the clinical outcome, it could potentially be useful in a high-risk group such as the elderly and multiply relapsed patients. Beyond prediction of toxicity, a better understanding of altered methylated derivatives generated owing to these polymorphisms has the potential to identify metabolic derivatives that are more effective with less toxicity compared to inorganic As 2 O 3 . A causal link between persistent activation of a lymphoid compartment and the occurrence of lymphoma is best established in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type. The contribution of such factors to T-cell neoplasia is unclear, although immunophenotypic attributes of T-cell large granular lymphocytic leukemia (T-LGL) indicate that this disease is derived from
